Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Breast Cancer

Interventions

DRUG

Pertuzumab

4 cycles of taxane, pertuzumab, trastuzumab

Trial Locations (1)

RECRUITING

Shanghai Jiaotong University School of Medicine affiliated Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Jiao Tong University School of Medicine

OTHER